The I-O Academy website is intended for healthcare professionals practising in Great Britain only. Prescribing and adverse event reporting information is available at the bottom of the page. Materials on this website have been optimised and approved for viewing on a desktop only. Content may not display correctly on mobile devices.

Home
I-O Services
Practical Management
Personalised Care
Podcasts
Events
Home
I-O Services
Practical Management
Personalised Care
Podcasts
Events
Home
I-O Services
Practical Management
Personalised Care
Podcasts
Events
Home
I-O Services
Practical Management
Personalised Care
Podcasts
Events
Home
I-O Services
Practical Management
Personalised Care
Podcasts
Events
Home
I-O Services
Practical Management
Personalised Care
Podcasts
Events
Home
I-O Services
Practical Management
Personalised Care
Podcasts
Events

bms logo

header

 

The BMS I-O Academy is an ongoing programme committed to the education and support of all the healthcare professionals who use, are considering prescribing, and are involved with the management of patients receiving BMS immune-oncology agents.

The website will enable access to educational resources and materials on immuno-oncology, and is for personal use only. In our commitment to support the educational needs of healthcare professionals, we strive to continually update our website to ensure you have access to the most recent resources.

 

 

Watch, Listen, Interact with BMS Medical Education

linkedin

Scan QR code with your mobile to experience I-O Academy on the go

 

 

 

 

 

Opdivo® (nivolumab) monotherapy and combination regimens.
Advanced (unresectable or metastatic) Melanoma: Opdivo® (nivolumab) and Yervoy® (ipilimumab).
Opdualag® (nivolumab-relatlimab) is indicated for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. This medicinal product is subject to additional monitoring.

 

 

7356-GB-2400326 - November 2024

 

Adverse events should be reported. Reporting forms and information can be found at: Great Britain - www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store; Adverse events should also be reported to Bristol Myers Squibb via medical.information@bms.com or 0800 731 1736